ResMed has lagged behind the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.

ResMed stock (ISIN US7611521078) was trading at USD 221.89 on Nasdaq on September 24, 2026, down 0.18 percent from the prior ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Setbacks for competitors have positioned ResMed to capture more market share.

ResMed stock closed at its last completed Nasdaq session on September 24, 2026, with the Nasdaq Composite ending at 26,939.37 ...

ResMed (RMD) shares are pushing higher on Tuesday after a senior RBC Capital Markets analyst upgraded the medical equipment ...

U.S. Indexes Extend Losing Streak; Oil Prices, Treasury Yields Surge Markets News, Sept. 2, 2026: Stocks Snap 3-Session Skid ...

ResMed has de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. Recurring mask and consumables revenue, now 42% of the sleep and breathing ...

An announcement from Resmed ( ) is now available. On August 31, 2026, ResMed Inc. entered into an accelerated share repurchase agreement with Citibank to buy back $450 million of ...

Resmed Inc. RMD continues to see strong demand for its market-leading AirSense 10 and AirSense 11 sleep devices. Expansion into international markets appears highly promising, supported by the company ...

The stock's rise snapped a nine-day losing streak. Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the ...

ResMed exemplifies the razor-and-blade model, leveraging inevitability, brand loyalty, inexpensive recurring costs, and a superior user experience. RMD dominates the sleep apnea market with a 62% ...